Vladislav I. Tiurin

Saint Petersburg, SPE 197758, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

Journal: International journal of molecular sciences

Published: June 27, 2026

Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia.

Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia.

Journal: Exploration of targeted anti-tumor therapy

Published: December 16, 2025

Novel kinase-activating genetic events in non-small cell lung carcinomas.

Novel kinase-activating genetic events in non-small cell lung carcinomas.

Journal: Exploration of targeted anti-tumor therapy

Published: April 04, 2025

Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.

Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.

Journal: International journal of molecular sciences

Published: September 27, 2024

Pathways and targeting avenues of BRAF in non-small cell lung cancer.

Pathways and targeting avenues of BRAF in non-small cell lung cancer.

Journal: Expert opinion on therapeutic targets

Published: June 28, 2024

Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.

Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.

Journal: Diagnostics (Basel, Switzerland)

Published: September 02, 2023

ALK, ROS1, RET and NTRK1-3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers.

ALK, ROS1, RET and NTRK1-3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers.

Journal: International journal of molecular sciences

Published: August 14, 2023

Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples.

Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples.

Journal: International journal of molecular sciences

Published: July 27, 2023

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas.

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas.

Journal: International journal of molecular sciences

Published: April 26, 2023

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.

Journal: International journal of molecular sciences

Published: January 28, 2023

Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.

Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.

Journal: Cancer medicine

Published: October 20, 2021

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.

Journal: Translational oncology

Published: February 03, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026